|Articles|July 31, 2013
Jules Mitchel: Thoughts on Risk-Based Monitoring
Jules Mitchel of Target Health discusses risk-based monitoring trends in the clinical trials industry
Advertisement
Jules Mitchel of Target Health discusses, his views on its importance of risk-based monitoring in the clinical trials industry, now that is such a popular topic.
SPOTLIGHT EVENT
Cambridge, MassachusettsDownload Brochure
RELATED
-
- Industry Metric Indicates Low ROI with Full Source Document Verification
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
5